GlobeNewswire

Sigma Designs Unlocks the Full Potential of the Smart Home with Next Generation Z-Wave 700-Series Chipset

Dela

LAS VEGAS, Jan. 08, 2018 (GLOBE NEWSWIRE) -- CES 2018 Venetian Ballroom - Sigma Designs® (NASDAQ:SIGM), a leading provider of intelligent system-on-chip (SoC) solutions for smart home IoT, today unveils its new 700-Series Z-Wave platform, which include numerous performance and technological enhancements in energy-efficiency and RF performance, while being cost-effective, built to power the context-aware smart home.

Z-Wave 700-Series is a long range, low power and future-proof hardware platform with integrated software tools and building blocks enabling a whole new generation of Z-Wave sensor devices. 700-Series will drive the battery-powered device trend, empowering Artificial Intelligence and Machine Learning systems to utilize sensor data and make smart homes smarter, safer, and more connected.

"Sigma's Z-Wave 700-Series chip will completely reshape the meaning of smart home. It solves for many of today's technological barriers, while being the most flexible, interoperable platform, bringing smart home functionality to a new level," said Raoul Wijgergangs, VP of Sigma Designs' Z-Wave Business Unit. "700-Series opens opportunities for new classes of sensors that weren't possible before, while making remarkable improvements to existing device categories. 700-Series is creating a path to full home installations, moving from tens of Z-Wave devices to hundreds of Z-Wave devices per home. Our new platform assures the environment that will take homes from smart to truly intelligent."

Key features of the 700-Series platform include:

  • Low power: 700-Series will have best-in-class low power radio performance enabling multiyear battery lifetime and more than 10-year sensor lifetime on a coin-cell.  
  • Long range: 700-Series platform will enable range of more than 300 feet, covering multi-stories in a house and the far end of the yard.
  • Low cost and fast time to market: 700-Series gets developers started fast with low cost developer kits, tools and readymade certified reference code ensuring minimum time from prototype to certified product.
  • High performance: Powerful ARM®-based platform with large memory on the chip and many peripherals, enabling intelligence at the edge with fast energy efficient computation and secure inclusion in less than one second.
  • Certified interoperable and backwards compatible: Every 700-Series device will have the highest level of security in the smart home with Z-Wave Security 2 (S2) framework and consistent easy install with Z-Wave SmartStart.  

The energy-efficient and long range wireless communication with the 700-Series Z-Wave platform, allows smart home sensors to go beyond the current limits. This means that smart homes can extend to the yard, the end of the driveway and seamlessly cover multiple stories in a home. The extremely low power consumption enables new small form factor Z-Wave sensors which can be embedded into new places such as into furniture, windows and even behind dry walls.  

The 700-Series platform will continue to utilize and build on top of core Z-Wave features such as S2 and SmartStart. Sigma's Security 2 (S2) architecture, which combines existing and new security features, allows Z-Wave to continue to be the safest, most secure ecosystem of smart devices on the global market. SmartStart is an easy way to automatically create and configure Z-Wave networks for instant device installation success. Comprising the new Z-Wave protocol and gateway software layers, SmartStart pre-configures devices to the network before they reach the home, dramatically reducing installation time, and thereby costs, to maximize return on investment (ROI) for installers and remove difficulty of DIY installations for homeowners.

About Sigma Designs
Sigma Designs, Inc. (NASDAQ:SIGM) is a world leader in enabling smart home convergence. The company designs and builds the essential semiconductor technologies that serve as the foundation for the world's leading Connected Smart TV platforms, and Internet of Things (IoT) for smart home devices. For more information about Sigma Designs, please visit www.sigmadesigns.com.

About Z-Wave
Z-Wave technology is an open internationally recognized ITU standard (G.9959). It is the leading wireless home control technology in the market today, with over 2400 certified interoperable products worldwide. Represented by the Z-Wave Alliance, and supported by more than 700 companies around the world, the standard is a key enabler of smart living solutions for home safety and security, energy, hospitality, office and light commercial applications. Z-Wave® is a registered trademark of Sigma Designs and its subsidiaries in the United States and other countries.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements about the anticipated features, benefits, capabilities and performance of Sigma's products and solutions, specifically Sigma's 700- series chipset. The following factors could cause actual results to differ materially from those in the forward-looking statement including but not limited to: general economic conditions, including the rate of adoption of Sigma's 700-series chipset, Sigma's ability to deploy and achieve market acceptance for the 700 series chipset and other products in its target markets, changes in technology, and other risks that are detailed from time to time in Sigma's SEC reports, including its annual report on Form 10-K. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Sigma undertakes no obligation to publicly release or otherwise disclose the result of any revision to these forward-looking statements that may be made as a result of events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Press Contacts:
Mary Miller 
Sigma Designs 
+1-510-897-1069 
Mary_Miller@sigmadesigns.com  

Alexandra Crabb
Caster Communications
+1-401-792-7080
alex@castercomm.com 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sigma Designs, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum